EMA Recommends Granting a Marketing Authorisation for Poherdy By Ogkologos - April 10, 2026 215 0 Facebook Twitter Google+ Pinterest WhatsApp It is a biosimilar of pertuzumab which was authorised in the EU in 2013 Source RELATED ARTICLESMORE FROM AUTHOR ESMO contributes to discussions on the future of cancer care at EU Cancer Mission event Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma MOST POPULAR ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of... July 1, 2025 Immunotherapy Drug Tebentafusp Improves Survival in Advanced Uveal Melanoma April 29, 2021 Mom Diagnosed With Stage III Breast Cancer While Nursing Her 9-Month-Old... May 20, 2020 CancerLand Bookshelf : Loosen July 26, 2021 Load more HOT NEWS Reunión anual de la American Society of Clinical Oncology de 2023:... A real Eureka moment for translation ΝΕΑ ΓΙΑ ΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ASCO Annual Meeting 2023: Improving Patients’ Lives Through Collaboration, Research, and...
